BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15986440)

  • 1. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
    Chua CW; Lee DT; Ling MT; Zhou C; Man K; Ho J; Chan FL; Wang X; Wong YC
    Int J Cancer; 2005 Dec; 117(6):1039-48. PubMed ID: 15986440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.
    Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC
    Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-allylcysteine, a water-soluble garlic derivative, suppresses the growth of a human androgen-independent prostate cancer xenograft, CWR22R, under in vivo conditions.
    Chu Q; Lee DT; Tsao SW; Wang X; Wong YC
    BJU Int; 2007 Apr; 99(4):925-32. PubMed ID: 17155983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
    Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase.
    Zhou C; Ling MT; Kin-Wah Lee T; Man K; Wang X; Wong YC
    Cancer Lett; 2006 Feb; 233(1):36-47. PubMed ID: 16473668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
    Ubai T; Azuma H; Kotake Y; Inamoto T; Takahara K; Ito Y; Kiyama S; Sakamoto T; Horie S; Muto S; Takahara S; Otsuki Y; Katsuoka Y
    Anticancer Res; 2007; 27(1A):75-88. PubMed ID: 17352219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
    Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
    Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation.
    Wang JD; Takahara S; Nonomura N; Ichimaru N; Toki K; Azuma H; Matsumiya K; Okuyama A; Suzuki S
    Prostate; 1999 Jun; 40(1):50-5. PubMed ID: 10344723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
    Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
    Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
    Pchejetski D; Bohler T; Brizuela L; Sauer L; Doumerc N; Golzio M; Salunkhe V; Teissié J; Malavaud B; Waxman J; Cuvillier O
    Cancer Res; 2010 Nov; 70(21):8651-61. PubMed ID: 20959468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
    Fox WD; Higgins B; Maiese KM; Drobnjak M; Cordon-Cardo C; Scher HI; Agus DB
    Clin Cancer Res; 2002 Oct; 8(10):3226-31. PubMed ID: 12374693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
    Dorai T; Cao YC; Dorai B; Buttyan R; Katz AE
    Prostate; 2001 Jun; 47(4):293-303. PubMed ID: 11398177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
    Chen CT; Gan Y; Au JL; Wientjes MG
    Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells.
    Shen Y; Cai M; Xia W; Liu J; Zhang Q; Xie H; Wang C; Wang X; Zheng S
    Cancer Lett; 2007 Sep; 254(2):288-97. PubMed ID: 17462818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
    Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
    Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.